Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 18 to 40 years on day of inclusion~* Informed consent form signed~* Able to attend all scheduled visits and to comply with all trial procedures~* For a woman, inability to bear a child or negative urine pregnancy test.~Exclusion Criteria :~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Previous participation in a clinical trial involving an investigational flu pandemic vaccine.~* Vaccination with an influenza vaccine during the past 6 months~* Any vaccination in the 4 weeks preceding the first trial vaccination~* Vaccination planned in the 4 weeks following any trial vaccination~* Breast-feeding.~* For a woman of child-bearing potential, the absence of an effective method of contraception or abstinence non observed for at least 4 weeks prior to the first vaccination and at least 4 weeks after the last vaccination.~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy.~* Known human immunodeficiency virus (HIV), hepatitis B (AgHBs) or hepatitis C seropositivity.~* Known systemic hypersensitivity to egg proteins, chick proteins, or to any of the vaccine components, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances.~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.~* Chronic illness at a stage that could interfere with trial conduct or completion.~* Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures.~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.~* Blood or blood-derived products received in the past 3 months.~* Febrile illness (temperature ≥ 37.5°C) on the day of inclusion.~* Laboratory abnormalities considered clinically significant upon the Investigator's judgment in blood sample taken at screening (for Step 1 only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Dose 1 with Adjuvant
- Group 2 (Type: EXPERIMENTAL): Dose 2 with adjuvant
- Group 3 (Type: EXPERIMENTAL): Dose 3 with adjuvant
- Group 4 (Type: EXPERIMENTAL): Dose 4 with adjuvant
- Group 5 (Type: ACTIVE_COMPARATOR): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).